Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

China Negotiates Shorter Exclusivity for US-Made Biologic Drugs

publication date: Apr 26, 2019

China has apparently negotiated a shorter patent protection period for new biologic drugs from the US, according to anonymous sources. New US biologics will have only eight years of protection under the new trade agreement, much shorter than the 12 years that is the rule in the US. The trade deal is still in negotiations, but US officials do not appear to be eager to fight for a longer exclusivity period. When pharma companies heard about the change, they complained. Reportedly, trade officials said the only alternative was no patent protection at all for new biologic drugs. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China